AstraZeneca, breast cancer
AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a setting in which Gilead’s rival Trodelvy significantly improved OS in a prior late-phase study.
Breast cancer is a common cancer in women, but early detection greatly improves treatment success. Knowing the signs and ...
Fashion and lifestyle influencer Bridget Bahl revealed she has breast cancer in an emotional Instagram video posted on Sunday ...
World Dense Breast Day emphasizes the need for awareness and advocacy for individuals with dense breasts, which can ...
Fact: While breast cancer is far more common in women, men can also develop it. Although rare, male breast cancer accounts for about 1% of all breast cancer cases. Men should also pay attention to any ...
In honor of Breast Cancer Awareness Month, KnitWell Group — Ann Taylor, Chico’s, Haven Well Within, Lane Bryant, LOFT, Soma, ...
October marks Breast Cancer Awareness Month – a timely reminder about the importance of breast cancer screenings, especially in light of new guidelines. With a focus on early detection and making ...
The Louisiana Cancer Foundation is providing free breast cancer screenings in October, and today, Susie Runkle joined Good Morning ArkLaMiss to talk about the event.
The Navy says its highest-ranking military officer has been successfully treated for early-stage breast cancer. The service ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback